Gavan, SP; Bruce, IN; Payne, K; Bruce, I; Lunt, M; Peek, N; Geifman, N; ... King, J; + view all Gavan, SP; Bruce, IN; Payne, K; Bruce, I; Lunt, M; Peek, N; Geifman, N; Armitt, G; Doherty, P; Prattley, J; Azadbakht, N; Papazian, A; Le Sueur, H; Farrelly, C; Richardson, C; Shabbir, Z; Hewitt, L; McHugh, N; Gordon, C; Reynolds, J; Young, S; Jayne, D; Farewell, V; Su, L; Pickering, M; Lightstone, E; Gilmore, A; Botto, M; Vyse, T; Morris, DL; D'Cruz, D; Vital, E; Wittmann, M; Emery, P; Beresford, M; Hedrich, C; Midgley, A; Gritzfeld, J; Ehrenstein, M; Isenberg, D; Parvaz, M; Dunnage, J; Batchelor, J; Holland, E; Upsall, P; Youssef, H; McCann, L; Mediwake, R; Bharadwaj, A; Vital, E; Kapur, D; Chee-Seng Yee, P; Griffiths, B; Yusuf, A; Zoma, A; Vermaak, E; Carlucci, F; Watts, R; Gordon, P; Shaffu, S; Wijeyekoon, J; McLaren, Z; Ahmad, Y; Batley, M; Gompels, L; Sheeran, T; Yi Yong, C; Jeffery, R; Hamdulay, S; Rahmeh, F; Young Min, S; Rhodes, B; De Lord, D; Lanyon, P; Chan, A; Teh, LS; Marks, J; Hutchinson, D; Regan, M; Haigh, R; Stratton, R; Rhys-Dillon, C; Akil, M; Mewar, D; Skeoch, S; Erb, N; O'Riordan, E; Bartram, S; Gayed, M; Dasgupta, B; Gunwardena, H; Pyne, D; Kaul, A; Mahindrakar, M; Raj Sood, B; Gullick, N; Edwards, C; Robson, JC; King, J; - view fewer (2022) Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases. Value in Health 10.1016/j.jval.2022.07.001. (In press).

Preview

Text 1-s2.0-S1098301522020976-main.pdf - Published Version Download (560kB) | Preview

Abstract

Objectives: This study aimed to demonstrate how to estimate the value of health gain after patients with a multisystem disease achieve a condition-specific composite response endpoint. Methods: Data from patients treated in routine practice with an exemplar multisystem disease (systemic lupus erythematosus) were extracted from a national register (British Isles Lupus Assessment Group Biologics Register). Two bespoke composite response endpoints (Major Clinical Response and Improvement) were developed in advance of this study. Difference-in-differences regression compared health utility values (3-level version of EQ-5D; UK tariff) over 6 months for responders and nonresponders. Bootstrapped regression estimated the incremental quality-adjusted life-years (QALYs), probability of QALY gain after achieving the response criteria, and population monetary benefit of response. Results: Within the sample (n = 171), 18.2% achieved Major Clinical Response and 49.1% achieved Improvement at 6 months. Incremental health utility values were 0.0923 for Major Clinical Response and 0.0454 for Improvement. Expected incremental QALY gain at 6 months was 0.020 for Major Clinical Response and 0.012 for Improvement. Probability of QALY gain after achieving the response criteria was 77.6% for Major Clinical Response and 72.7% for Improvement. Population monetary benefit of response was £1 106 458 for Major Clinical Response and £649 134 for Improvement. Conclusions: Bespoke composite response endpoints are becoming more common to measure treatment response for multisystem diseases in trials and observational studies. Health technology assessment agencies face a growing challenge to establish whether these endpoints correspond with improved health gain. Health utility values can generate this evidence to enhance the usefulness of composite response endpoints for health technology assessment, decision making, and economic evaluation.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item